Sweet syndrome induced by epidermal growth factor receptor (EGFR) inhibitors, 2022.
A case of Sweet's syndrome triggered by erlotinib, an epidermal growth factor receptor inhibitor.
"Epidermal growth factor receptor inhibitors are associated with multiple cutaneous toxicities, with PRIDE (papulo-pustules or paronychia, regulatory abnormalities of hair growth, itching and dryness) syndrome being the most frequently observed adverse cutaneous effect. We report a case of Sweet syndrome induced by epidermal growth factor receptor inhibitors.
A 72-year-old woman, with recently diagnosed stage IV epidermal growth factor receptor-mutated non-small-cell lung carcinoma, was admitted to Prince of Wales Hospital in Hong Kong for painful rashes for five days and a fever of one-day duration. Two weeks before admission, she was started on oral erlotinib 150 mg daily. "
Initially misdiagnosed as papulopustular eruption due to erlotinib, with secondary infection. Treatment with antibiotics doxycycline, amoxicillin-clavulanic acid, cefotaxime, and meropenem unsuccessful (doxycycline is a tetracycline antibiotic that reduces inflammation. It's sometimes used in the treatment of Sweet's syndrome because of its anti-inflammatory effect, but doesn't work in all cases).
"A diagnosis of drug-induced Sweet syndrome was made. Prednisolone 30 mg daily was started and the patient became afebrile after three days, with skin lesions completely resolving in two weeks. Prednisolone was then tapered by 10 mg every two weeks and was completely stopped after a six-week treatment course." ijdvl.com/sweet-syndrome-in...
